February 18, 2011
Novartis gains positive CHMP opinion for Rasilamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure
February 17, 2011
Novartis appoints Naomi Kelman as new Head of the Novartis OTC division
- Novartis OTC (Over-the-Counter) to become separate division in the group's diversified healthcare portfolio with Kelman reporting to Joseph Jimenez, CEO of Novartis
February 10, 2011
Novartis studies show Onbrez® Breezhaler® plus tiotropium provided greater increase in lung function than tiotropium alone
February 09, 2011
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET, study published in NEJM shows
-
RADIANT-3 trial shows everolimus more than doubled median progression-free survival from 4.6 to 11.0 months versus placebo[1]
-
No tumor growth after 18 months in 34% of the patients treated with everolimus versus in 9% of those treated with placebo[1]
-
These data, previously reported at oncology congresses, support worldwide regulatory submissions for treatment of advanced neuroendocrine tumors (NET), which has received priority review designation by US FDA
January 31, 2011
FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for use in children from 2 years of age
January 27, 2011
Innovation drives Novartis to double-digit growth for 2010
worldwide offices | stay connected | contact | help | sitemap
